Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease. [MLN-0002_401]
ID Number 16-2343Principal Investigator(s)
James F Marion
Department(s) or Division(s)
Entyvio PASS is a long-term safety observational study to look at the safety and efficacy of vedolizumab compared to other biologic agents in treating Inflammatory Bowel Disease (IBD) such as Crohn's Disease (CD) and Ulcerative Colitis (UC). Vedolizumab was approved by the FDA on May 20, 2014 under the trade name Entyvio to treat Ulcerative Colitis and Crohn's Disease. This study will not be administering any drugs in connection with this observational study, but rather to gather data on medication that is approved and being prescribed for IBD according to normal medical treatment.
Recruiting Patients: Yes